Pronova BioPharma ASA: Files Second Patent Infringement Action in Response to Par and Teva's Paragraph IV Notifications related to Lovaza(TM)

Pronova BioPharma ASA (OSE:　 PRON.OL) ("Pronova
BioPharma") announces that Pronova BioPharma Norge AS filed two individual lawsuits; one
against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively
"Par") and one against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries
Ltd. (collectively "Teva") in the United States District Court for the District of
Delaware asserting infringement of Pronova BioPharma's U.S. Patent No. 7,732,488 ("the
'488 Patent", entitled "Pharmaceutical Composition Comprising Low Concentrations of
Environmental Pollutants"). The '488 Patent was listed in the FDA Orange Book on 2 July
2010 and expires in 2025.　 The lawsuits are in response to Par and Teva's Paragraph IV
Certification Notices to Pronova BioPharma related to the '488 Patent.